Sotan is mainly used to treat malignant tumors, such as advanced hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and thyroid cancer. In clinical trials, Sotan can delay the growth of gastrointestinal stromal tumors and reduce the size of renal cell tumors. Sotan can also reduce tumor angiogenesis, cause cancer cell apoptosis, and finally shrink the tumor.
However, Sotan also has some adverse reactions, such as nausea, vomiting, diarrhea and abnormal liver function. When using Sotan, patients need to take it in strict accordance with the doctor's advice, and they need regular check-ups. In a word, Sotan is an effective anticancer drug, but the indications and medication methods need to be strictly controlled.